Market closedADR
Adagene/$ADAG
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Adagene
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Ticker
$ADAG
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
174
Website
Adagene Metrics
BasicAdvanced
$93M
Market cap
-
P/E ratio
-$0.72
EPS
0.65
Beta
-
Dividend rate
Price and volume
Market cap
$93M
Beta
0.65
52-week high
$4.38
52-week low
$1.35
Average daily volume
87K
Financial strength
Current ratio
2.5
Quick ratio
2.422
Long term debt to equity
8.26
Total debt to equity
36.74
Interest coverage (TTM)
-38.43%
Management effectiveness
Return on assets (TTM)
-19.59%
Return on equity (TTM)
-45.70%
Valuation
Price to revenue (TTM)
113.9
Price to book
1.65
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
-3.264
Growth
Revenue change (TTM)
-96.40%
Earnings per share change (TTM)
-15.23%
3-year revenue growth (CAGR)
-22.47%
3-year earnings per share growth (CAGR)
-33.86%
What the Analysts think about Adagene
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Adagene stock.
Adagene Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Adagene Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Adagene News
AllArticlesVideos
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
GlobeNewsWire·1 month ago
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
GlobeNewsWire·2 months ago
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Adagene stock?
Adagene (ADAG) has a market cap of $93M as of December 14, 2024.
What is the P/E ratio for Adagene stock?
The price to earnings (P/E) ratio for Adagene (ADAG) stock is 0 as of December 14, 2024.
Does Adagene stock pay dividends?
No, Adagene (ADAG) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Adagene dividend payment date?
Adagene (ADAG) stock does not pay dividends to its shareholders.
What is the beta indicator for Adagene?
Adagene (ADAG) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.